Evidence analysisNovember 10, 2026Health & Science
Scientific advice for veterinary medicines

FreedomWitness Evidence Engine: This is an AI-assisted original analysis built from the linked source and available public source context. It separates evidence from interpretation and may challenge conventional framing only where the evidence supports it. It is not a copied article.
Scientific Advice on Veterinary Medicines: An Evidence Overview
What is established
The European Medicines Agency (EMA) provides scientific advice to companies developing veterinary medicines. This service aims to guide medicine developers on the appropriate tests and studies during the development phase to support marketing authorization applications. The advice is intended to promote the development and availability of veterinary medicines that are high-quality, effective, and acceptably safe.
The advice process is coordinated primarily by the Committee for Medicinal Products for Veterinary Use (CVMP) and the Scientific Advice Working Party for veterinary products (SAWP-V). Applicants submit requests through EMA’s secure IRIS platform, which facilitates communication and document exchange. Additionally, EMA collaborates with the United States Food and Drug Administration’s Center for Veterinary Medicine (FDA-CVM) to offer parallel scientific advice for products intended for authorization in both Europe and the US. This joint procedure seeks to optimize product development, harmonize regulatory expectations, and reduce duplicative testing.
What the source claims
- EMA’s scientific advice service provides developers with guidance on appropriate study designs and tests in veterinary medicine development.
- The process is regulated with specific timelines and administrative guidance to help applicants prepare and submit their questions.
- An online platform (IRIS) is central to submission and communication, streamlining interactions between medicine developers and EMA.
- Parallel scientific advice procedures between EMA and FDA-CVM have been enhanced since June 2024, with more defined timelines, extra meetings, and preliminary written feedback to applicants.
- These joint procedures are based on confidentiality agreements between the European Commission, EMA, and FDA-CVM.
What may be missing from the usual framing
The source material focuses on regulatory procedures, scientific advice provision, and collaboration between regulatory bodies but does not discuss:
- The impact of this advice on the actual speed or success rates of veterinary medicine approvals.
- Details about how conflicts of interest are managed in the advisory process or transparency around industry influence.
- Whether small or less-resourced companies have equal access and support compared to large pharmaceutical companies.
- Potential criticisms or controversies regarding the scientific advice system or delays introduced by the process itself.
Competing evidence or uncertainty
The EMA webpage does not provide empirical data or independent analysis on the effectiveness or outcomes of the scientific advice programs. Evidence is insufficient to conclude how much the scientific advice accelerates development timelines or improves medicine safety and efficacy in practice.
The nature and extent of the EMA-FDA collaboration could also raise questions of regulatory harmonization versus national regulatory sovereignty. While the joint advice aims to streamline development and reduce redundancy, there may be stakeholders concerned about regulatory capture, data-sharing implications, or the complexity added by meeting dual agency expectations.
Currently, no detailed public evaluation or independent reviews of the scientific advice procedures are referenced.
Why it matters
Veterinary medicines affect animal health, food safety, and one health considerations linking animal and human health. Scientific advice during medicine development shapes how quickly and effectively novel veterinary treatments become available.
Understanding EMA’s scientific advice mechanisms provides insight into how regulatory bodies interact with pharmaceutical companies and the checks intended to ensure medicines’ quality and safety. The parallel advice between EMA and FDA also reflects broader international cooperation trends in regulating veterinary products.
Scrutiny of regulatory advice processes, transparency about their operation, and open sharing of outcomes are important for public trust and accountability in veterinary pharmaceutical governance.
What to verify next
- Independent evaluations or academic studies assessing the impact of EMA’s scientific advice on veterinary medicine approval efficiency and safety outcomes.
- Transparency measures and conflict of interest policies governing the scientific advice committees.
- User experiences—from both large and small medicine developers—regarding accessibility, responsiveness, and practical benefits of the advice.
- Comparative analyses of EMA-FDA parallel advice effectiveness versus separate regulatory processes.
- Any publicly available minutes, reports, or audits of the scientific advice process and committee deliberations.
Readers are encouraged to consult the original European Medicines Agency source page for the most current and detailed procedural documents and updates on veterinary scientific advice.
Source & verification
Primary source: What's new · November 9, 2026
FreedomWitness links to the original source so readers can inspect the underlying material and judge the context for themselves.
Continue reading

EudraGMDP database
What is established The EudraGMDP database is an established European Union (EU) information system managed by the European Medicines Agency (EMA). It serves as…

Antimicrobial resistance in the EU/EEA (EARS-Net) – Annual Epidemiological Report for 2025
Evidence Dossier: Antimicrobial Resistance Trends in the EU/EEA 2025 Antimicrobial Resistance Trends in the EU/EEA: Evidence from the 2025 EARS-Net Report What is established…

Rapid risk assessment – Carbapenem-resistant Enterobacterales, fourth update
Evidence Dossier: Carbapenem-resistant Enterobacterales (CRE) in the EU/EEA – Latest Scientific Assessment What is established Carbapenem-resistant Enterobacterales (CRE), which include bacteria such as Klebsiella…